HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.
Gagliardini, R., Rossetti, B., Bianco, C., Rusconi, S., Colafigli, M., Prinapori, R., Francisci, D., Fantauzzi, A., Orofino, G., Vignale, F., Di Giambenedetto, S., De Luca, A., Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study, Abstract de <<HIV Drug Therapy Glasgow Congress 2014>>, (Glasgow, 02-06 November 2014 ), <<JOURNAL OF THE INTERNATIONAL AIDS SOCIETY>>, 2014; 17 (4 Suppl 3): 19818-19818. 10.7448/IAS.17.4.19818 [http://hdl.handle.net/10807/61288]
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
Gagliardini, Roberta;Rossetti, Barbara;Bianco, Claudia;Colafigli, Manuela;Di Giambenedetto, Simona;De Luca, Andrea
2014
Abstract
HIV/HCV coinfection is a risk factor for hepatic injury in patients receiving HAART and previous studies support a favourable effect of antiretroviral regimens including maraviroc (MVC) on the course of coinfection compared with other antiretroviral drugs. There are few observations about MVC use in simplified treatment of coinfected patients.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
